News

A recent study may indicate the need for future research to assess the relationship between pain and the anterior chamber depth.

Dexamethasone implant is key to treating non-infectious posterior segment uveitis.

Investigators at Mount Sinai report that ocular cells may be infected directly by the virus, with the limbus especially susceptible.

There are more people with vision loss and blindness than previously estimated, according to a new study supported by Prevent Blindness.

Delivering existing therapeutics through alternative routes may offer option.

The U.S. Patent and Trademark Office issued today two patents to Ocuphire Pharma covering the late-stage product candidate Nyxol (phentolamine mesylate).

Experts discuss durability of action and atrophy inhibitor among primary treatment goals.

After a US District judge rules against request for preliminary injunction, Johnson & Johnson Vision moves forward with litigation in several countries, including the United States, to resolve intellectual property disputes against Alcon.

According to investigators, understanding the ocular manifestations in patients with COVID-19 could ultimately help with the diagnosis and prevent transmission.

Mark Pennesi, MD, PhD, reports during ARVO 2021 that preliminary results have shown that AGTC-401 and AGTC-402 seem safe and well tolerated in patients with ACHM.

Investigators examine the demographic, refractive, PRO data measure.

Observation over the long term is needed to determine treatment efficacy.

A study led by investigators at St. Michael's Hospital of Unity Health Toronto supports pneumatic retinopexy as a primary retinal reattachment technique to achieve better long-term integrity of photoreceptors.

A word from Chief Medical Editor Peter J. McDonnell, MD.

Ocuphire Pharma has completed enrollment in the VEGA-1 Phase 2 clinical trial evaluating the safety and efficacy of drops to treat presbyopia.

Advancements in imaging make ICL an effective option for a wider range of patients.

Ophthalmologists at New York Eye and Ear Infirmary of Mount Sinai have created a new technique to evaluate patients with sickle cell retinopathy and assess the disease before it progresses and leads to permanent vision loss.

In an announcement that could impact ophthalmologists, the Department of Health and Human Services’ Office for Civil Rights revealed this week that it will enforce a prohibition of discrimination on the basis of sexual orientation and gender identity.

Oculis reported positive data from two of its clinical proof-of-concept phase 2 trials for OCS-02, a novel topical anti-TNF alpha antibody fragment candidate, for the treatment of dry eye disease and acute anterior uveitis.

Option has a broader biologic effect for patients.

Graybug Vision’s Phase 2b ALTISSIMO trial of GB-102 focuses on the treatment of wet age-related macular degeneration.

Friederike Kortuem, MD, MSc, discusses how treatment with voretigene neparvovec-rzyl led to a short-term change in the foveal morphology in a patient with visual impairment that included nyctalopia and decreased visual acuity in early childhood.

Findings from retrospective study support intraoperative cefuroxime irrigation.

Worldwide increase in technologies for ophthalmic use is dramatic.

Check out the latest cartoon!

Joseph Grieco, PhD, notes that treatment fills a gap for patients who are unresponsive to the standard treatments for noninfectious keratitis.